An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries

Khan, Sakif Ahamed; Das, Proma Rani; Nahar, Zabun; Dewan, Syed Masudur Rahman

doi:10.1177/20503121241239538

Cited by 3 publications

(1 citation statement)

References 51 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This autoimmune mechanism involves the immune system mistaking the body's tissues for a foreign invader. Autoimmune neurological conditions like GBS and MFS share this delayed presentation and underlying mechanism [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

Isolated Self-Limited Right Oculomotor Nerve Palsy With Positive Asialo-GM1 Antibody After SARS-CoV-2 mRNA Vaccination

Ozobu,

Salter,

Salter

et al. 2024

Cureus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Isolated Self-Limited Right Oculomotor Nerve Palsy With Positive Asialo-GM1 Antibody After SARS-CoV-2 mRNA Vaccination

Ozobu,

Salter,

Salter

et al. 2024

Cureus

View full text Add to dashboard Cite

Impact of the COVID-19 pandemic and vaccination on global, regional, and national burden of Guillain-Barré syndrome: observational study

Gào,

Zhao,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

ObjectivesTo estimate the global, regional, and national burden and trends of Guillain-Barré Syndrome (GBS), and to explore the impact of the COVID-19 pandemic and related public health measures on the GBS burden.DesignObservational study.Setting204 countries and territories.Data sourcesGlobal Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 and Our World in Data.Main outcome measuresAll-cause and COVID-19-specific age-standardized years lived with disability (YLD) rates and estimated annual percentage change (EAPC).ResultsGlobally, the burden of GBS significantly increased during the COVID-19 pandemic, age-standardized YLD rates were 0.86 (95% uncertainty interval (UI): 0.56 to 1.24) per 100,000 people in 2020, rising to 1.75 (95% UI: 1.12 to 2.54) per 100,000 people in 2021, reflecting an EAPC of 70.35% (95% UI: 38.73 to 109.06) from 2019 to 2021. Regionally, the highest age-standardized YLD rates in 2020 and 2021 were observed in the high-income Asia Pacific and central Latin America, respectively, while the lowest rates were found in East Asia for both years. Age-standardized YLD rates rose 3.7 times faster in countries with a low socio-demographic index (SDI) versus countries with a high SDI (103.21% per year (95% UI: 71.10 to 141.35%) vs 28.02% per year (11.46 to 47.03)). Males generally had higher YLD rates across all age groups, with the highest disparity in those aged 80 and above. During the first two years of the pandemic, the increase in YLD rates was more pronounced in females and younger populations aged 15-29 years. A statistically negative correlation was observed between COVID-19 vaccination coverage and the GBS burden, with increases in full vaccination coverage per 100 people leading to decreases in all-cause YLD rates by 0.0070 and COVID-19-specific YLD rates by 0.0128 per 100,000 people.ConclusionPredominantly driven by the surge of COVID-19 cases, the burden of GBS significantly increased during the first two years of the pandemic, especially in those countries with lower SDI levels. Greater increases in the GBS burden were observed in females and younger populations (15-29 years). Importantly, the benefits of vaccination outweighed the risks in controlling the post-COVID-19 GBS burden, although significant disparities in vaccination coverage existed between countries. These findings offer robust evidence facilitating public education and transparent communication on COVID-19 vaccination and highlight the urgency for targeted control measures to manage the burden of post-infection complications, such as GBS, during future COVID-19 waves or other potential pandemics.WHAT IS ALREADY KNOWN ON THIS TOPICGuillain-Barré syndrome (GBS) is an autoimmune disease, and respiratory and gastrointestinal infections are the major triggering factors.From 1990 to 2019, the burden of GBS was relatively low, with negligible changes observed in most countries and territories.The impact of the COVID-19 pandemic and vaccination on the burden of GBS remains not fully understood.WHAT THIS STUDY ADDSDuring the COVID-19 pandemic, the global age-standardized years lived with disability (YLD) related to GBS increased by 70.30% annually, and low socio-demographic index (SDI) regions experienced the most rapid GBS burden increment (103.21%).The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was the primary factor contributing to the increased burden of GBS during the COVID-19 pandemic.Improving vaccination coverage was the most effective measure to reduce the post-COVID-19 burden of GBS, and each additional fully vaccinated person (per hundred people) decreased the COVID-19-specific age-standardized YLD of GBS by 0.0128 per 100,000 population.

show abstract

Complete genome sequence of Edwardsiella tarda strain GBS0709 isolated from a Japanese patient with the acute motor axonal neuropathy subtype of Guillain–Barré syndrome

Imajoh,

Mori,

Shimizu

et al. 2024

Microbiol Resour Announc

View full text Add to dashboard Cite

show abstract

An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries

Cited by 3 publications

References 51 publications

Isolated Self-Limited Right Oculomotor Nerve Palsy With Positive Asialo-GM1 Antibody After SARS-CoV-2 mRNA Vaccination

Isolated Self-Limited Right Oculomotor Nerve Palsy With Positive Asialo-GM1 Antibody After SARS-CoV-2 mRNA Vaccination

Impact of the COVID-19 pandemic and vaccination on global, regional, and national burden of Guillain-Barré syndrome: observational study

Complete genome sequence of Edwardsiella tarda strain GBS0709 isolated from a Japanese patient with the acute motor axonal neuropathy subtype of Guillain–Barré syndrome

Contact Info

Product

Resources

About